CALTCalliditas Therapeutics AB

Nasdaq calliditas.se


$ 19.41 $ 1.29 (6.9 %)    

Tuesday, 30-Apr-2024 11:08:43 EDT
QQQ $ 427.43 $ 2.19 (0.52 %)
DIA $ 382.31 $ 0.79 (0.21 %)
SPY $ 504.99 $ 0.59 (0.12 %)
TLT $ 88.87 $ 0.65 (0.74 %)
GLD $ 213.12 $ 0.66 (0.31 %)
$ 19.9399
$ 19.41
$ 19.35 x 100
$ 21.00 x 100
$ 19.41 - $ 19.41
$ 15.25 - $ 29.30
694
na
1.19B
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 calliditas-announces-nefigard-open-label-extension-results

Calliditas Therapeutics AB (NASDAQ:CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open...

 calliditas-therapeutics-presents-additional-data-analyses-from-phase-3-neflgard-trial-of-nefecon-in-primary-iga-nephropathy-at-isn-world-congress-of-nephrology-2024

Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefeco...

 calliditas-receives-notice-of-allowance-for-us-patent-application-covering-setanaxib-in-cancer-treatment

Calliditas Therapeutics AB (NASDAQ:CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has ...

 earlier-reported-everest-medicines-partner-calliditas-therapeutics-announces-us-fda-grants-an-additional-seven-year-orphan-drug-exclusivity-period-for-nefecon

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics A...

 calliditas-bags-an-additional-seven-year-orphan-drug-exclusivity-period-for-tarpeyo-from-the-fda

Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has gran...

 hc-wainwright--co-reiterates-buy-on-calliditas-therapeutics-maintains-50-price-target

HC Wainwright & Co. analyst Arthur He reiterates Calliditas Therapeutics (NASDAQ:CALT) with a Buy and maintains $50 pric...

 palo-alto-networks-issues-weak-outlook-joins-teladoc-health-solaredge-technologies-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday.

 calliditas-therapeutics-q4-epads-006-beats-007-estimate-sales-4241m-beat-3586m-estimate

Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate ...

 calliditas-therapeutics-announces-that-the-us-patent-and-trademark-office-issued-patent-11896719-entitled-new-pharmaceutical-compositions-on-january-24-2024-with-validity-as-of-today-february-13-2024

Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX))) ("Calliditas") today announced that the United Stat...

 whats-going-on-with-vera-therapeutics-stock-today

Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst rating...

 calliditas-therapeutics-clocked-preliminary-net-tarpeyo-revenues-of-31m33m-in-q4-fy23-preliminary-net-tarpeyo-revenues-of-100m102m-up-170-yoy-fy23-preliminary-total-revenues-of-110m113m

Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare di...

 why-douyu-international-shares-are-trading-higher-by-14-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share ...

 neogenomics-energy-fuels-and-other-big-stocks-moving-lower-on-thursday

U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ:...

 why-carmax-shares-are-trading-higher-by-around-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.

 calliditas-therapeutics-scores-complete-fda-approval-broader-label-for-lead-kidney-disease-drug

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the lo...

 micron-posts-upbeat-sales-joins-calliditas-therapeutics-and-other-big-stocks-moving-higher-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.

 calliditas-therapeutics-ab-announced-that-the-fda-approved-tarpeyo-delayed-release-capsules-to-reduce-the-loss-of-kidney-function-in-adults-with-primary-immunoglobulin-a-nephropathy-at-risk-for-disease-progression

TARPEYO (investigational name NEFECON) is the only FDA-approved treatment for IgAN to significantly reduce the loss of kidney f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION